Three questions with Rich Taylor: Alzheimer's and Brain Awareness Month

Rich Taylor

June is Alzheimer’s and Brain Awareness Month, which seemed a particularly apt time to talk with Rich Taylor, a University of Notre Dame researcher whose research focuses on the discovery and development of new therapeutic leads for the treatment of unmet clinical needs in a number of diseases, including Alzheimer’s. Taylor is associate vice president for research, professor of chemistry and biochemistry and interim director of the Warren Family Research Center for Drug Discovery and Development.

Read More

CO-ADD Offers Antibiotic ESKAPE Screens

The Community forOpen Antimicrobial Drug Discovery (CO-ADD) is a Wellcome Trust funded, non-for-profit, openframework for discovery and development of new therapies against multidrug-resistant (MDR) bacteria ( based at The University of Queensland in Australia.

CO-ADD will perform primary antibacterial screening for academic research groups as a free service and makes no claims on results or IP.

Read More

Funding Opportunity through Indiana CTSI Molecular Therapeutics Program

Molecular Therapeutics Program Early Stage Drug Discovery Support

Seed funding, up to $10,000, and advice is available for researchers seeking to develop early stage drug discovery projects. 


The Molecular Therapeutics Program, a part of the Indiana Clinical and Translational Sciences Institute, seeks applications for a competitive program that will provide funds and essential consultation to support the early stage development of therapeutics. This opportunity is provided in concert with the newly established Indiana Drug Discovery Alliance (IDDA), a clearinghouse for drug discovery and development resources at the Indiana-CTSI member institutions of Indiana University, Purdue University and the University of Notre Dame.

Read More

Researchers identify molecular mechanism responsible for making malaria parasites drug-resistant

Red blood cells infected with the malaria parasite P. falciparum at the "ring" stage, either sensitive or resistant to artemisinins

University of Notre Dame researchers led an international team to identify a molecular mechanism responsible for making malaria parasites resistant to artemisinins, the leading class of antimalarial drugs.

According to the World Health Organization’s 2014 World Malaria Report, there are an estimated 198 million cases of malaria worldwide with 3.3 billion people at risk for contracting the infection. Although the impact of malaria is still significant, the statistics reflect a considerable reduction in the global malaria burden. Since 2010, disease transmission has been reduced by 30 percent and mortality due to malaria has decreased by almost half.

Read More

Warren Family Center hosted a visitor from Novartis Pharmaceutical Corporation

Warren Family Center hosted a visitors from Novartis Pharmaceutical Corporation including Susan Giacalone (Area Scientific Associate Director- Field Medical MSL, Rare Diseases), Julio Fernandez (Field Medical National Director, Rare Diseases), John Murry, (Regional Scientific Director), Beth Ostergard Stillwell (Oncology Regional Scientific Director).…

Read More

New antibiotic holds promise against antibiotic-resistant infections

Mayland Chang, left, and Shahriar Mobashery

Estimates of deaths from methicillin-resistant Staphylococcus aureus (MRSA) in the United States range upwards of 19,000 annually. Around 1960, when Staphylococcus aureus developed resistance to first-generation penicillin, methicillin and other second-generation beta-lactam antibiotics were adopted to fight the illness. The modern variants of the bacterium have developed resistance to the four drugs now used to treat it.

A team of researchers led by Shahriar Mobashery and Mayland Chang at the University of Notre Dame has discovered a promising new antibiotic, a vital weapon against disease as pathogens evolve to develop resistance to long-used drugs.

Read More